The Food and Drug Administration (FDA) has approved Qdolo (tramadol hydrochloride oral solution; Athena Bioscience) for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Qdolo contains tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin reuptake. Because of the risks of addiction, abuse and misuse with opioids, even at recommended doses, Qdolo should be reserved for use in patients for whom alternative treatment options have not been tolerated or have not provided adequate analgesia.
Qdolo is supplied as a clear, grape flavored solution containing 5mg/mL of tramadol hydrochloride. Patients are strongly advised to always use a calibrated oral dosing device to correctly measure the prescribed amount. Qdolo should not be used concomitantly with other tramadol-containing products.
For more information visit athenabioscience.com.
- Qdolo [package insert]. Athens, GA: Athena Bioscience, LLC; 2020.
This article originally appeared on MPR